RNA.US Atrium Therapeutics, Inc. Common Stock

Healthcare Biotechnology USA Stocks
6.48 USD
Close of Nov 17, 2026
6.36 16.77
Market cap
USD 140M
P/E
-
P/B
0.79x
ROE
-26.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is RNA.US undervalued?

Graham number

The Graham number of Atrium Therapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Atrium Therapeutics, Inc. Common Stock fundamental analysis

No fundamental analysis for Atrium Therapeutics, Inc. Common Stock yet.

Atrium Therapeutics, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Atrium Therapeutics, Inc. Common Stock

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of gene…

Full company profile